| Ytd | -38.26% | |
| 1y | -30.62% |
| Open | 7.28 | Prev Close | 7.17 | Low | 6.73 | High | 7.28 | Mkt Cap | 62.46M |
| Vol | 716.00 | Avg Vol | 9.41K | EPS | -1.20 | P/E | N/A | Forward P/E | N/A |
| Beta | 2.93 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 6.40 | 200-d Avg | 9.52 | 1yr Est | 0.00 |
EXOZ News
eXoZymes (NASDAQ: EXOZ) outlined progress toward commercializing its NCT program, including a report
eXoZymes NASDAQ: EXOZ outlined progress toward commercializing its NCT program, including a reported
Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday&#
Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / Aug
Optimized process delivered a 10-fold improvement in productivity, significantly improving the estim
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform ab
eXoZymes Inc. (NASDAQ: EXOZ - Get Free Report)'s stock price dropped 1.1% on Monday. The stock trade
Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins design
Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins design
Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential f
Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential f
LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Comp
eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enz
LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or
LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") -
LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")
Management to Host Conference Call Today at 5:30 PM Eastern LOS ANGELES, CA / ACCESS Newswire / Marc
LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")
LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")
LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")
eXoZymes (NASDAQ: EXOZ - Get Free Report) and Curis (NASDAQ: CRIS - Get Free Report) are both small-
LOS ANGELES, CALIFORNIA / ACCESS Newswire / February 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) (
eXoZymes (NASDAQ: EXOZ - Get Free Report) and Disc Medicine (NASDAQ: IRON - Get Free Report) are bot
N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted sci
N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted sci